• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI SuperconnectorNEW
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI SuperconnectorNEW
  • Settings
  • RSS Feeds
PublishGo to AppAI Superconnector
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEW
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form 144 filed by RadNet Inc.

    9/10/25 6:29:31 PM ET
    $RDNT
    Medical Specialities
    Health Care
    Get the next $RDNT alert in real time by email
    Form 144 Filer Information UNITED STATES
    SECURITIES AND EXCHANGE COMMISSION
    Washington, D.C. 20549

    Form 144

    NOTICE OF PROPOSED SALE OF SECURITIES
    PURSUANT TO RULE 144 UNDER THE SECURITIES ACT OF 1933

    FORM 144

    144: Filer Information

    Filer CIK
    0000929967
    Filer CCC
    XXXXXXXX
    Is this a LIVE or TEST Filing? Radio button checked LIVE Radio button not checked TEST

    Submission Contact Information

    Name
    Phone
    E-Mail Address

    144: Issuer Information

    Name of Issuer
    RadNet, Inc.
    SEC File Number
    001-33307
    Address of Issuer
    1510 COTNER AVE
    LOS ANGELES
    CALIFORNIA
    90025
    Phone
    3104787808
    Name of Person for Whose Account the Securities are To Be Sold
    HAMES NORMAN R
    See the definition of "person" in paragraph (a) of Rule 144. Information is to be given not only as to the person for whose account the securities are to be sold but also as to all other persons included in that definition. In addition, information shall be given as to sales by all persons whose sales are required by paragraph (e) of Rule 144 to be aggregated with sales for the account of the person filing this notice.

    Relationship to Issuer
    Officer

    144: Securities Information

    Title of the Class of Securities To Be SoldName and Address of the BrokerNumber of Shares or Other Units To Be SoldAggregate Market ValueNumber of Shares or Other Units OutstandingApproximate Date of SaleName the Securities Exchange
    Common
    Raymond James & Associates
    880 Carillon Parkway
    St. Petersburg � FL � 33716
    10000726892.007691606209/10/2025
    NASDAQ


    Furnish the following information with respect to the acquisition of the securities to be sold and with respect to the payment of all or any part of the purchase price or other consideration therefor:

    144: Securities To Be Sold

    Title of the ClassDate you AcquiredNature of Acquisition TransactionName of Person from Whom AcquiredIs this a Gift?Date Donor AcquiredAmount of Securities AcquiredDate of PaymentNature of Payment *
    Common05/02/2017RSUIssuerCheckbox not checked1000005/02/2017Cash

    * If the securities were purchased and full payment therefor was not made in cash at the time of purchase, explain in the table or in a note thereto the nature of the consideration given. If the consideration consisted of any note or other obligation, or if payment was made in installments describe the arrangement and state when the note or other obligation was discharged in full or the last installment paid.



    Furnish the following information as to all securities of the issuer sold during the past 3 months by the person for whose account the securities are to be sold.

    144: Securities Sold During The Past 3 Months

    Nothing to ReportCheckbox checked

    144: Remarks and Signature

    Remarks
    Date of Notice
    09/10/2025

    ATTENTION:

    The person for whose account the securities to which this notice relates are to be sold hereby represents by signing this notice that he does not know any material adverse information in regard to the current and prospective operations of the Issuer of the securities to be sold which has not been publicly disclosed. If such person has adopted a written trading plan or given trading instructions to satisfy Rule 10b5-1 under the Exchange Act, by signing the form and indicating the date that the plan was adopted or the instruction given, that person makes such representation as of the plan adoption or instruction date.
    Signature
    Maressia Rooks-Bailey, as duly authorized representative of Raymond James & Associates, Inc., as attorney-in-fact for Norman Hames

    ATTENTION: Intentional misstatements or omission of facts constitute Federal Criminal Violations (See 18 U.S.C. 1001)

    Get the next $RDNT alert in real time by email

    Crush Q3 2025 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $RDNT

    DatePrice TargetRatingAnalyst
    6/13/2025$69.00Buy
    B. Riley Securities
    3/5/2025$85.00 → $65.00Outperform → Strong Buy
    Raymond James
    9/6/2024$57.00 → $79.00Equal Weight → Overweight
    Barclays
    3/6/2024$48.00Equal Weight
    Barclays
    8/31/2023$40.00Buy
    Truist
    3/31/2023$30.00Market Outperform
    CJS Securities
    3/3/2023$30.00Mkt Perform → Outperform
    Raymond James
    8/12/2021Outperform → Market Perform
    Raymond James
    More analyst ratings

    $RDNT
    SEC Filings

    View All

    SEC Form 144 filed by RadNet Inc.

    144 - RadNet, Inc. (0000790526) (Subject)

    9/10/25 6:29:31 PM ET
    $RDNT
    Medical Specialities
    Health Care

    SEC Form 10-Q filed by RadNet Inc.

    10-Q - RadNet, Inc. (0000790526) (Filer)

    8/11/25 4:37:00 PM ET
    $RDNT
    Medical Specialities
    Health Care

    RadNet Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits

    8-K - RadNet, Inc. (0000790526) (Filer)

    8/11/25 6:09:19 AM ET
    $RDNT
    Medical Specialities
    Health Care

    $RDNT
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    B. Riley Securities initiated coverage on RadNet with a new price target

    B. Riley Securities initiated coverage of RadNet with a rating of Buy and set a new price target of $69.00

    6/13/25 7:50:00 AM ET
    $RDNT
    Medical Specialities
    Health Care

    RadNet upgraded by Raymond James with a new price target

    Raymond James upgraded RadNet from Outperform to Strong Buy and set a new price target of $65.00 from $85.00 previously

    3/5/25 7:50:00 AM ET
    $RDNT
    Medical Specialities
    Health Care

    RadNet upgraded by Barclays with a new price target

    Barclays upgraded RadNet from Equal Weight to Overweight and set a new price target of $79.00 from $57.00 previously

    9/6/24 7:50:42 AM ET
    $RDNT
    Medical Specialities
    Health Care

    $RDNT
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    EVP and Chief Legal Officer Katz David Jeffrey gifted 4,593 shares, decreasing direct ownership by 5% to 82,181 units (SEC Form 4)

    4 - RadNet, Inc. (0000790526) (Issuer)

    9/12/25 8:36:49 PM ET
    $RDNT
    Medical Specialities
    Health Care

    Pres and COO-West Operations Hames Norman R sold $727,400 worth of shares (10,000 units at $72.74), decreasing direct ownership by 4% to 239,183 units (SEC Form 4)

    4 - RadNet, Inc. (0000790526) (Issuer)

    9/12/25 5:10:50 PM ET
    $RDNT
    Medical Specialities
    Health Care

    Pres & CEO, Digital Health Wesdorp Cornelis sold $35,995 worth of shares (500 units at $71.99), decreasing direct ownership by 0.92% to 53,995 units (SEC Form 4)

    4 - RadNet, Inc. (0000790526) (Issuer)

    9/10/25 4:27:19 PM ET
    $RDNT
    Medical Specialities
    Health Care

    $RDNT
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    RadNet, Inc. to Present at the Morgan Stanley 23rd Annual Global Healthcare Conference on Tuesday, September 9th, 2025

    LOS ANGELES, Sept. 08, 2025 (GLOBE NEWSWIRE) -- RadNet, Inc. (NASDAQ:RDNT), a national leader in providing high-quality, cost-effective diagnostic imaging services through a network of fully-owned and operated outpatient imaging centers, today announced that Dr. Howard Berger, President and Chief Executive Officer, Mark Stolper, Executive Vice President and Chief Financial Officer, and Mital Patel, Executive Vice President of Financial Planning & Analysis and Chief Administrative Officer, will be presenting at the Morgan Stanley 23rd Annual Global Healthcare Conference on Tuesday, September 9th, 2025 at 04:50 p.m. Eastern Time. There will be simultaneous and archived webcasts available

    9/8/25 12:51:55 PM ET
    $RDNT
    Medical Specialities
    Health Care

    Healthcare AI Market Explodes 38.5% Annually as Diagnostics Gain FDA Traction

    USA News Group News CommentaryIssued on behalf of Avant Technologies Inc. VANCOUVER, BC, Aug. 12, 2025 /PRNewswire/ -- USA News Group News Commentary – Research and development of new AI-powered tech is causing a major overhaul in the healthcare sector, with experts both optimistic and horrified at the same time. Analysts at market.us are forecasting the global AI in healthcare market to hit nearly $700 billion by 2034, growing at an explosive 38.5% CAGR along the way. With new technologies getting closer to full FDA approval, now one of the biggest hurdles for AI in healthcare is gaining the trust of clinicians and patients alike, all while proving efficacy of these new solutions. From an i

    8/12/25 11:09:00 AM ET
    $BFLY
    $CLOV
    $RDNT
    Medical Electronics
    Health Care
    Medical Specialities
    Biotechnology: Biological Products (No Diagnostic Substances)

    RadNet Reports Second Quarter Financial Results with Record Quarterly Revenue and Adjusted EBITDA¹ and Revises Upwards 2025 Financial Guidance Ranges

    Total Company Revenue increased 8.4% to a quarterly record of $498.2 million in the second quarter of 2025 from $459.7 million in the second quarter of 2024; Revenue from the Digital Health reportable segment (inclusive of intersegment revenue) increased 30.9% to a quarterly record of $20.7 million in the second quarter of 2025 from $15.8 million in the second quarter of 2024Total Company Adjusted EBITDA(1) was a quarterly record of $81.2 million in the second quarter of 2025 as compared with $72.3 million in the second quarter of 2024, an increase of 12.3%; Digital Health reportable segment Adjusted EBITDA(1) increased 4.1% to $3.4 million in the second quarter of 2025 from $3.3 million in

    8/10/25 4:00:00 PM ET
    $RDNT
    Medical Specialities
    Health Care

    $RDNT
    Leadership Updates

    Live Leadership Updates

    View All

    RadNet, Inc. Announces the Appointment of Kees Wesdorp as President and Chief Executive Officer of RadNet's Digital Health Division

    Former Chief Business Leader of Philips' multi-billion-dollar Precision Diagnosis division and member of Philips' Executive CommitteeEnd-to-end responsibility for Philip's CT, MR, dXR, Ultrasound and Diagnostic Informatics (radiology software) businessesProven track record of building and managing radiology software solutions, including significant experience with AI development and commercialization LOS ANGELES, Sept. 12, 2024 (GLOBE NEWSWIRE) -- RadNet, Inc. (NASDAQ:RDNT), a national leader in providing high-quality, cost-effective diagnostic imaging services through a network of fully-owned and operated outpatient imaging centers and digital health solutions, announced today the appo

    9/12/24 6:00:00 AM ET
    $RDNT
    Medical Specialities
    Health Care

    $RDNT
    Financials

    Live finance-specific insights

    View All

    RadNet Reports Second Quarter Financial Results with Record Quarterly Revenue and Adjusted EBITDA¹ and Revises Upwards 2025 Financial Guidance Ranges

    Total Company Revenue increased 8.4% to a quarterly record of $498.2 million in the second quarter of 2025 from $459.7 million in the second quarter of 2024; Revenue from the Digital Health reportable segment (inclusive of intersegment revenue) increased 30.9% to a quarterly record of $20.7 million in the second quarter of 2025 from $15.8 million in the second quarter of 2024Total Company Adjusted EBITDA(1) was a quarterly record of $81.2 million in the second quarter of 2025 as compared with $72.3 million in the second quarter of 2024, an increase of 12.3%; Digital Health reportable segment Adjusted EBITDA(1) increased 4.1% to $3.4 million in the second quarter of 2025 from $3.3 million in

    8/10/25 4:00:00 PM ET
    $RDNT
    Medical Specialities
    Health Care

    RadNet, Inc. Announces Date of its Second Quarter 2025 Financial Results Conference Call

    LOS ANGELES, July 25, 2025 (GLOBE NEWSWIRE) -- RadNet, Inc. (NASDAQ:RDNT), a national leader in providing high-quality, cost-effective diagnostic imaging services through a network of owned and operated outpatient imaging centers and digital health solutions, announced today that it will host a conference call to discuss its second quarter 2025 financial results on Monday, August 11, 2025 at 7:30 a.m. Pacific Time (10:30 a.m. Eastern Time). Investors are invited to listen to RadNet's conference call by dialing 844-826-3035. International callers can dial 412-317-5195. There will also be simultaneous and archived webcasts available at https://viavid.webcasts.com/starthere.jsp?ei=1729070&

    7/25/25 6:00:00 AM ET
    $RDNT
    Medical Specialities
    Health Care

    RadNet's Wholly-Owned Subsidiary, DeepHealth, Completes Acquisition of iCAD

    Acquisition contributes iCAD's commercial, technology, and regulatory capabilitiesThe acquisition positions DeepHealth with an industry-leading suite of AI-powered breast cancer image interpretation and workflow solutionsThe combination is expected to provide acceleration of AI adoption and expanded worldwide access to advanced breast cancer screening and diagnosis technologies LOS ANGELES, July 17, 2025 (GLOBE NEWSWIRE) --  RadNet, Inc. (NASDAQ:RDNT) ("RadNet"), a national leader in providing high-quality, cost-effective diagnostic imaging services and digital health solutions, announced today that it has completed the acquisition of iCAD, Inc. (NASDAQ:ICAD) ("iCAD"), a global lead

    7/17/25 9:00:00 AM ET
    $ICAD
    $RDNT
    Medical/Dental Instruments
    Health Care
    Medical Specialities

    $RDNT
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    Amendment: SEC Form SC 13G/A filed by RadNet Inc.

    SC 13G/A - RadNet, Inc. (0000790526) (Subject)

    11/12/24 4:51:53 PM ET
    $RDNT
    Medical Specialities
    Health Care

    Amendment: SEC Form SC 13G/A filed by RadNet Inc.

    SC 13G/A - RadNet, Inc. (0000790526) (Subject)

    11/4/24 1:22:38 PM ET
    $RDNT
    Medical Specialities
    Health Care

    Amendment: SEC Form SC 13G/A filed by RadNet Inc.

    SC 13G/A - RadNet, Inc. (0000790526) (Subject)

    10/24/24 6:36:21 PM ET
    $RDNT
    Medical Specialities
    Health Care